TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany.
TherapeutAix UG, Juttastrasse 18, 52066 Aachen, Germany.
Drug Discov Today. 2024 Nov;29(11):104207. doi: 10.1016/j.drudis.2024.104207. Epub 2024 Oct 11.
Idiopathic pulmonary fibrosis (IPF) is an area of high unmet clinical need and high research activity in the pharmaceutical and biotech industries. The two approved therapies, nintedanib and pirfenidone, have issues with efficacy and tolerability. Despite a considerable number of development programs reaching late-stage Phase 2b or 3 clinical trials, no drug other than nintedanib and pirfenidone has successfully demonstrated a benefit for patients. An analysis of these failures, and consideration of the trajectories of some of the current development projects, may offer novel paradigms for choosing modes-of-action and for the development of successful drugs.
特发性肺纤维化（IPF）是制药和生物技术行业中一个高度未满足临床需求和高研究活跃度的领域。两种已批准的疗法，尼达尼布和吡非尼酮，在疗效和耐受性方面存在问题。尽管有相当数量的开发项目进入了后期的 2b 期或 3 期临床试验，但除了尼达尼布和吡非尼酮之外，没有其他药物成功证明对患者有益。对这些失败的分析，以及对一些当前开发项目轨迹的考虑，可能为选择作用模式和开发成功药物提供新的范例。
